APA (7th ed.) Citation

Boere, I., Edelson, M., Hietanen, S., Gilbert, L., Gold, M., Sukhina, O., . . . Cloven, N. (2025). 1118P Time to quality of life (QoL) deterioration in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/rEC) and by population subgroups in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Annals of Oncology, 36, S744. https://doi.org/10.1016/j.annonc.2025.08.1755

Chicago Style (17th ed.) Citation

Boere, I.A, et al. "1118P Time to Quality of Life (QoL) Deterioration in Patients (pts) with Mismatch Repair Proficient/microsatellite Stable (MMRp/MSS) Primary Advanced or Recurrent Endometrial Cancer (pA/rEC) and by Population Subgroups in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial." Annals of Oncology 36 (2025): S744. https://doi.org/10.1016/j.annonc.2025.08.1755.

MLA (9th ed.) Citation

Boere, I.A, et al. "1118P Time to Quality of Life (QoL) Deterioration in Patients (pts) with Mismatch Repair Proficient/microsatellite Stable (MMRp/MSS) Primary Advanced or Recurrent Endometrial Cancer (pA/rEC) and by Population Subgroups in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial." Annals of Oncology, vol. 36, 2025, p. S744, https://doi.org/10.1016/j.annonc.2025.08.1755.